However, even in fresh samples, GFAP measured in blood was superior to CSF measurements in discriminating between amyloid‐positive and amyloid‐negative individuals (thereby reflecting AD pathology), suggesting that the matrix discrepancy is likely not solely because of sample stability and alterations in GFAP aggregation. This evidence concerns the gene GFAP and Alzheimer disease.